# Pizarra — PT-pseudo_d5ceb6b4204f (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d5ceb6b4204f
Task: 1

Encounter: Urology - outpatient on 13 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 72-year-old male
  - PSA: 4.1 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.181 ng/mL²
  - PSA velocity: 0.77 ng/mL/yr
  - Prior PSA: 3.3 ng/mL
  - Prostate volume: 22.65 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8003183 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 4.1 ng/mL. PI-RADS 4. PSAD 0.18. Prostate volume 23 mL. csPCa 0.80.

Vitals: weight 90 kg, height 173 cm, BMI 30.1, BP 130/80 mmHg, HR 58 bpm. Smoking: Ex-smoker (10 pack-yr, quit 2021).

Chief complaint: Clinical reassessment prompted by a PSA increase to 4.1 ng/mL alongside a previously confirmed positive biopsy result.

History: A 72-year-old retired bus driver, widowed, entered the workup for a PSA elevation in mid-2023, a value that has now climbed to 4.1 ng/mL. He resides in an assisted-living facility situated over 90 minutes from the hospital, prompting a preference for telephone monitoring when clinically suitable. Despite his years, his lifestyle remains vigorous; he jogs 5 km three times each week and experiences only slight urinary bother, scoring a 7 on the IPSS. Tobacco use ceased entirely in 2021 after accumulating 10 pack-years, and he avoids alcohol. No comorbidities are present, and he takes no medications. Unrelated recent medical encounters include a dermatology visit for actinic keratosis monitoring and a completed six-session physiotherapy regimen addressing mechanical lower back pain. He maintains baseline functionality without systemic complaints.

Physical examination: DRE — texture: uniformly smooth; mobility: unrestricted; asymmetry: absent. The prostate appears symmetrically benign with no palpable nodules, confirming a normal digital rectal assessment. General inspection shows a well-nourished gentleman free of acute distress, maintaining stable vital signs and clear breath sounds. Abdominal palpation yields no masses or organomegaly, remaining entirely unremarkable.

Patient info: retired bus driver; Widowed; Lives in assisted-living facility.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Running 3x/week, 5 km; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Dermatology — actinic keratosis check; Physiotherapy — lower back, six sessions.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.58 +/- 0.13   (95% CI 0.32-0.85)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.13  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.98 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and patient agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with the current PSA rise and imaging findings, warrants a re-biopsy or deferral, as the initial panel is inconclusive. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which includes PSA (4.1 ng/mL), PI-RADS 4, prior positive biopsy, and csPCa probability (0.8003183). It cannot account for the context that the prior biopsy was positive, which fundamentally changes the question from "does he have cancer?" to "is the current finding progression or recurrence?" It also ignores the specific PSA velocity (0.77 ng/mL/yr) and the DRE finding (Normal), which are crucial contextual factors not fully integrated into the initial classification.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested BIOPSY with $p=0.58 \pm 0.13$, placing it in the 'discuss' tier where the model cannot distinguish between yes/no. This uncertainty is high, suggesting the panel is insufficient. Specifically, the model likely failed to weigh the conflict between the prior positive biopsy and the current PI-RADS 4 score, or the rising PSA velocity, which could lead to an incorrect suggestion. The high aleatoric uncertainty ($H=0.98$) indicates the disagreement lies in the data itself, meaning the model cannot resolve the ambiguity inherent in this specific clinical scenario.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement?

GUIDELINE ANCHOR
The guideline search indicates that the decision hinges on whether the prior grade is documented, whether the lesion changed against a previous MRI, and whether a surveillance re-biopsy is due.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_d5ceb6b4204f", "radiology_report": "Subject: Multiparametric MRI of the Prostate | Date: 10 Jan 2025 | Facility: Amsterdam UMC (AMC campus)\n\nClinical indication: Surveillance after a previously positive biopsy; current PSA stands at 4.1 ng/mL with clinical suspicion for clinically significant disease.\n\nFINDINGS:\nThe gland measures 22.65 mL in volume. T2-weighted sequences highlight an asymmetric focal hypointensity in the right mid-gland peripheral zone, spanning roughly 12 mm. Diffusion-weighted imaging shows marked restriction, mirrored by correspondingly low apparent diffusion coefficient values. Dynamic contrast enhancement demonstrates early, focal uptake compared to adjacent tissue. There is no evidence of extraprostatic extension or seminal vesicle invasion. The central zone appears normal without notable benign enlargement. Pelvic lymph nodes are unremarkable. Skeletal survey reveals no suspicious osseous abnormalities.\n\nIMPRESSION:\nPI-RADS 4 lesion situated in the right mid-gland peripheral zone.\nProstate volume 22.65 mL; PSA density 0.181 ng/mL/mL.\ncsPCa predicted probability 0.8003183."}
get_psa_trend
{"case_id": "PT-pseudo_d5ceb6b4204f", "psa_trend": [{"date": "Jul 2023", "val": 1.0}, {"date": "Jan 2024", "val": 1.2}, {"date": "Jul 2024", "val": 3.4}, {"date": "Jan 2025", "val": 4.1}]}
get_previous_notes
{"case_id": "PT-pseudo_d5ceb6b4204f", "previous_notes": [{"date": "18 May 2024", "author": "Dr. C. Peters (GP)", "text": "18 May 2024 - Dr. C. Peters (GP)\nConsultation focused on tracking the ascending PSA trajectory. An earlier reading from July 2023 recorded 1.7 ng/mL, followed by a January 2024 measurement of 2.2 ng/mL. The individual notes stable, mild lower urinary tract complaints while continuing a consistent running schedule. Laboratory panels were ordered to track the progression, and a specialist urology referral was processed given the steady increase and the history of a previously positive biopsy."}, {"date": "23 Jul 2023", "author": "Dr. C. Peters (GP)", "text": "23 Jul 2023 - Dr. C. Peters (GP)\nStandard check-in following the first PSA elevation. The latest result measures 1.7 ng/mL, sitting just above the standard laboratory reference range. Urinary function remains unaffected, and he continues residing in his assisted-living residence. A follow-up PSA test was planned for January to calculate velocity, accompanied by routine metabolic panels."}]}
NOT RETRIEVED
laboratory_results
Left closed because the moderator's agenda did not explicitly require the full lab panel, and the specific questions for this decision were answered by the other retrieved documents.
WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 4 lesion in the right mid-gland peripheral zone, suggesting a focal area of concern.
- PSA trend: Rising trend from 1.0 ng/mL (Jul 2023) to 4.1 ng/mL (Jan 2025), indicating progression.
AGAINST sampling this patient now:
- Previous notes: Prior biopsy result is documented, and no prior grade is explicitly stated in the retrieved notes.
- MRI report: No comparison with a previous MRI was explicitly detailed in the retrieved report, making it unclear if the lesion is new or changed.
WHERE THIS LEANS
The evidence suggests progression (rising PSA) and a suspicious finding on the current MRI (PI-RADS 4), but the lack of documented prior grade or comparison makes the decision ambiguous.
LEAN: unclear

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=abstains, evidence=abstains.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved documents confirm rising PSA and a current PI-RADS 4 finding, but the crucial information regarding the prior biopsy grade and comparison against prior imaging is missing, which is required by the guideline criterion.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

The decision leans toward biopsy because the statistical prior suggested it, and the guideline criterion abstained due to missing documentation on the prior biopsy grade. The rising PSA trend from 1.0 ng/mL to 4.1 ng/mL indicates progression, and the PI-RADS 4 finding on the MRI suggests a focal area of concern. Although the prior positive biopsy status is noted, the absence of a documented prior grade means the biopsy is necessary to determine if the lesion has progressed or if a surveillance pathway is warranted.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=important, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
